Nancy Pire-Smerkanich, DRSc, MS
Faculty Directory

Nancy Pire-SmerkanichDRSc, MS

Nancy Pire-SmerkanichDRSc, MS

Assistant Professor of Regulatory and Quality Sciences

Department of Regulatory and Quality Sciences

Nancy Pire-Smerkanich, DRSc, MS, is an assistant professor in the Department of Regulatory and Quality Sciences at the USC School of Pharmacy. She received her faculty appointment after successfully completing her doctoral dissertation on “Benefits Risk Frameworks – Implementation in Industry” in 2015.

In addition to teaching in courses related to drug development and clinical trials, she continues to provide regulatory guidance to industry peers. She brings to academia many years of practical regulatory knowledge and experience from industry, where she participated in all regulatory aspects of product development, having served as regulatory liaison, U.S. agent and global regulatory lead across all therapeutic areas.

Known for her dedication to education and mentoring across industry, Pire-Smerkanich continues to be recognized for her ability to provide accurate, relevant and dynamic instruction on both the technical and strategic aspects of global regulatory affairs and for her service to professional organizations such as the Drug Information Association and The Organization for Professionals in Regulatory Affairs.

Areas of Expertise

  • Regulatory Filing Strategy
  • Clinical Regulatory Guidance
  • Drug Development
  • Education

    USC

    MS and DRSc

    University of Connecticut

    BS

    University of Connecticut

    BA

  • Links
  • Selected Articles

    The Regulatory Landscape of Products to Treat Opioid Overdose

    Journal of Clinical and Translational Science
    Pooja Singh, Kaylene Okada, Amelia Spinrad, Nancy Pire-Smerkanich, Eunjoo Pacifici

    2019 Since 1971, Naloxone has been the only FDA approved opioid antagonist indicated for use after opioid overdose. New formulations of Naloxone have been introduced into the market, including an injectable, auto-injector, and nasal spray. However, Naloxone is short-acting and as such often requires multiple doses and may induce severe withdrawal symptoms. This study examines the regulatory framework to understand the evolution of products indicated to treat opioid overdose and the landscape of therapies in development. Furthermore, this study examines how the Food and Drug Administration (FDA) and other government agencies have approached the opioid crisis.

    Read More

    An Analysis of Current Trends in Inclusion of Historically Underrepresented Populations in Clinical Trials: Women and Geriatrics

    Journal of Clinical and Translational Science
    Jacqueline Chen, Kaitlyn Park, Sun Young Uhm, Amelia Spinrad, Apurva Uniya, Nancy Pire-Smerkanich, Eunjoo Pacifici

    2019 Clinical trials (CTs) play an important role in developing new treatments, expanding or refining treatments that are already available, and/or identifying behavioral changes that can prolong or improve the lives of subjects. CTs are also conducted to understand normal human physiology, pathophysiology, and factors associated with health outcomes. Results from CTs are then used to determine the safety and efficacy of medications or treatment. CT participants should reflect the diversity of those receiving the treatments because, exclusion of specific populations in CTs may potentially result in knowledge gaps for clinicians and regulators. Historically, women and geriatrics have been underrepresented as CT participants. For women, this is the result of Food and Drug Administration (FDA) action in 1977 which restricted women with childbearing potential from participating in phase I and early phase II CTs after thousands of birth defects resulted from thalidomide usage during pregnancy. While the U.S. Government Accountability Office’s 1992 and 2001 reports documented an increased female inclusion in later stages of CTs, earlier phases of CTs were still lacking. Likewise, older adults and geriatrics have been excluded in CTs arbitrarily or to avoid adverse events associated with drug-drug interactions and comorbidities. Over the past few decades, the FDA has worked to address this issue and increase diversity and transparency in CTs. In 2015, the FDA’s Action Plan for Food and Drug Administration Safety and Innovation Act (FDASIA) Section 907 called for improved CT inclusion and reporting of demographic subgroups (sex, age, race, and ethnicity), highlighting three priority areas: quality, participation, and transparency. This research examines the current state of female inclusion in phase I and II CTs (2016 to 2017) and geriatric inclusion in phase III CTs (2010 to 2017).

    Read More

    Ensuring Quality in Investigator-Initiated Clinical Trials through Monitoring Concepts Training

    Journal of Clinical and Translational Science
    Amelia Spinrad, Nancy Pire-Smerkanich, Eunjoo Pacifici, Apurva Uniyal, Annie Xie, Annie Ly, Advaita Chandramohan

    2019 Because clinical trial results are instrumental in the approval of a new drug or changes to the practice of medicine, ensuring the accuracy and validity of collected data is critical in the clinical trial process. This function, routinely carried out by clinical trial monitors in industry-sponsored trials, is often lacking in investigator-initiated trials (IITs) conducted in academia. To address this challenge, we have developed a self-study module that can be used to cross-train academic researchers in essential concepts and practical approaches to monitoring. Furthermore, we are applying a framework drawn from implementation science in the development and launch of this initiative. This framework, as used in other educational programs, is employed here to close the gap between initiative and practice, thereby effectively disseminating this training would improve the quality of clinical trials in academia.

    Read More

  • Accomplishments

    Outstanding Volunteer Service Award, DIA

    2004, 2017